Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg

DRUG2 trials

Sponsors

ViiV Healthcare

Conditions

Healthy SubjectsInfection, Human Immunodeficiency Virus

Phase 1

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

CompletedNCT01366547

ViiV HealthcareHealthy Subjects, Infection, Human Immunodeficiency Virus

Start: 2011-06-30End: 2011-07-31Updated: 2011-08-08

Evaluation of the Bioequivalence of a Combined Formulated Tablet

CompletedNCT01622790

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2012-06-30End: 2012-08-31Updated: 2012-10-15

Related Papers

Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.

2014-08-0122 citations